Pfizer zooms on getting nod to enter into Marketing and Supply Agreement with Mylan Pharmaceuticals
Pfizer is currently trading at Rs. 4345.25, up by 250.70 points or 6.12% from its previous closing of Rs. 4094.55 on the BSE.
The scrip opened at Rs. 4081.05 and has touched a high and low of Rs. 4477.20 and Rs. 4081.05 respectively. So far 26224 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 6452.85 on 02-Sep-2024 and a 52 week low of Rs. 4012.65 on 12-Feb-2025.
Last one week high and low of the scrip stood at Rs. 4477.20 and Rs. 4054.00 respectively. The current market cap of the company is Rs. 19832.10 crore.
The promoters holding in the company stood at 63.92%, while Institutions and Non-Institutions held 19.54% and 16.54% respectively.
Pfizer has received approval for a proposal to enter into a Marketing and Supply Agreement with Mylan Pharmaceuticals (Mylan) for Marketing and Sale of two brands of the Company, viz., Ativan and Pacitane. The said Marketing and supply agreement will be for a period of 5 years within the territory of India.
Mylan has a good presence in Central Nervous System therapy area with skilled resources for engagement with super specialists namely Neurologist and Psychiatrist. This arrangement with Mylan will enhance distribution and in clinic presence of the products of the company. The Board of Directors of the company at their Meeting held on February 20, 2025 has approved the same.
Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
